The effect of synbiotic adjunct therapy on clinical and paraclinical outcomes in hospitalized COVID‐19 patients: A randomized placebo‐controlled trial

Vaezi, Mahsa; Ravanshad, Sahar; Rad, Mostafa; Zarrinfar, Hossein; Kabiri, Mona

doi:10.1002/jmv.28463

Cited by 13 publications

(30 citation statements)

References 54 publications

(143 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four studies ( 22 , 28 , 29 , 31 ) reported the CRP serum level (mg/L). High heterogeneity was identified using Cochrane's Q test (df = 3, I 2 = 91%, P < 0.00001).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

BackgroundMulti system symptoms such as gastrointestinal tract and respiratory tract exist in coronavirus disease 2019 (COVID-19) patients. There is a lack of reliable evidence to prove that probiotics are effective in improving these symptoms. In this study, we aimed to evaluate the efficacy of probiotics in meta-analysis.MethodsWe systematically searched PubMed, Embase, Web of Science, and Cochrane Library up to February 15, 2023. Randomized controlled trials or high quality retrospective studies comparing the efficacy of probiotics as supplementation with non-probiotics in improving symptoms for patients with COVID-19 were included. This meta-analysis assessed endpoints using Review Manager 5.3.ResultTen citations comprising 1198 patients with COVID-19 were included. The results showed that probiotics could increase the number of people with overall symptom improvement (RR = 1.62, 95% CI [1.10, 2.38], P = 0.01) and shorten the duration (days) of overall symptoms (MD = −1.26, 95% CI [−2.36, −0.16], P = 0.02). For the duration (days) of specific symptoms, probiotics could improve diarrhea (MD = −2.12, 95% CI [−2.41, −1.83], P < 0.00001), cough (MD = −2.21, 95% CI [-4.56, 0.13], P = 0.06) and shortness of breath (MD = −1.37, 95% CI [-2.22, −0.53], P = 0.001). Probiotics had no obvious effect on fever, headache and weakness. For inflammation, probiotics could effectively reduce C-reactive Protein (CRP) serum level (mg/L) (MD = −4.03, 95% CI [−5.12, −2.93], P < 0.00001). Regarding hospital stay (days), probiotics group was shorter than non-probiotics group (MD = −0.98, 95% CI [−1.95, −0.01], P = 0.05).ConclusionTo some extent probiotics could improve the overall symptoms, inflammatory reaction and shorten hospital stay of patients with COVID-19. Probiotics may improve gastrointestinal symptoms (such as improving intestinal flora and reducing the duration of diarrhea) and further improve respiratory symptoms through the gut-lung axis.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=398309, identifier: CRD42023398309.

show abstract

“…Four studies ( 22 , 28 , 29 , 31 ) reported the CRP serum level (mg/L). High heterogeneity was identified using Cochrane's Q test (df = 3, I 2 = 91%, P < 0.00001).…”

Section: Resultsmentioning

confidence: 99%

“…Five studies ( 22 , 25 , 28 , 30 , 31 ) reported the hospital stay (days). A total of 776 patients included, 387 in the probiotics group and 389 in the non-probiotics group.…”

Section: Resultsmentioning

confidence: 99%

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The results showed that the inflammatory factor and cognitive status changed significantly, but the cognitive score did not, suggesting a potential benefit of probiotics in immunity regulation. 155 Similarly, Vaezi et al 138 included 78 patients with COVID-19 and randomly administered placebo or synbiotic capsules containing Lactobacillus, Bifidobacterium, and Streptococcus probiotics. After two daily interventions for 14 days, the level of interleukin 6 in the synbiotic supplementation group was significantly reduced.…”

Section: Probiotics Alleviate Uncomfortable Symptoms Of Covid-19mentioning

confidence: 99%

“…After two daily interventions for 14 days, the level of interleukin 6 in the synbiotic supplementation group was significantly reduced. 138 In addition, Catinean et al 156 suggested that patients receiving probiotic supplementation (five strains of bacillus; least one month) may experience faster symptom resolution. Adjunctive therapy of Limosilactobacillus reuteri PBS072 and Bifidobacterium breve BB077 for 30 days improved the quality of sleep and mood, thus reliving stress.…”

Section: Probiotics Alleviate Uncomfortable Symptoms Of Covid-19mentioning

confidence: 99%

“…Recent bibliometric analysis has revealed the immunomodulatory properties of probiotics in patients with COVID‐19, highlighting their prospects for the adjuvant treatment of COVID‐19. We summarize the recently published clinical trials of probiotics for the treatment of COVID‐19 in Table 1 138–144 . Supplementing probiotics may reduce inflammatory markers and regulate immune function.…”

Section: Microbiota‐based Implications For Therapeutic Interventionsmentioning

confidence: 99%

See 1 more Smart Citation

Alterations in microbiota of patients with COVID‐19: implications for therapeutic interventions

Qiu,

Mo,

Chen

et al. 2024

MedComm

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) recently caused a global pandemic, resulting in more than 702 million people being infected and over 6.9 million deaths. Patients with coronavirus disease (COVID‐19) may suffer from diarrhea, sleep disorders, depression, and even cognitive impairment, which is associated with long COVID during recovery. However, there remains no consensus on effective treatment methods. Studies have found that patients with COVID‐19 have alterations in microbiota and their metabolites, particularly in the gut, which may be involved in the regulation of immune responses. Consumption of probiotics may alleviate the discomfort caused by inflammation and oxidative stress. However, the pathophysiological process underlying the alleviation of COVID‐19‐related symptoms and complications by targeting the microbiota remains unclear. In the current study, we summarize the latest research and evidence on the COVID‐19 pandemic, together with symptoms of SARS‐CoV‐2 and vaccine use, with a focus on the relationship between microbiota alterations and COVID‐19‐related symptoms and vaccine use. This work provides evidence that probiotic‐based interventions may improve COVID‐19 symptoms by regulating gut microbiota and systemic immunity. Probiotics may also be used as adjuvants to improve vaccine efficacy.

show abstract

A comprehensive review of synbiotics: an emerging paradigm in health promotion and disease management

Lee,

Choi,

Choi

et al. 2024

World J Microbiol Biotechnol

View full text Add to dashboard Cite

The effect of synbiotic adjunct therapy on clinical and paraclinical outcomes in hospitalized COVID‐19 patients: A randomized placebo‐controlled trial

Cited by 13 publications

References 54 publications

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

Alterations in microbiota of patients with COVID‐19: implications for therapeutic interventions

A comprehensive review of synbiotics: an emerging paradigm in health promotion and disease management

Contact Info

Product

Resources

About